Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al
Tread carefully, and you should have quality solutions available for your critical research
J.et al (2022d)
Note also that the compounding market tightened in 2025 to 2026 after the FDA removed semaglutide and tirzepatide from shortage, so pharmacy access to compounded products now generally requires a documented clinical rationale
Pushback against California bill to limit access to GLP-1 Tenille Davis, chief advocacy officer for the Alliance for Pharmacy Compounding, is not in favor of limiting the ability to compound to GLP-1s
A substantial breakfast or lunch provides fuel when you need it most